Vandetanib Plus Chemotherapy for Induction Followed by Vandetanib or Placebo As Maintenance for Patients with Advanced Non–Small-Cell Lung Cancer: A Randomized Phase 2 PrECOG Study (PrE0501)-Reference-Cited by-同舟云学术

Vandetanib Plus Chemotherapy for Induction Followed by Vandetanib or Placebo As Maintenance for Patients with Advanced Non–Small-Cell Lung Cancer: A Randomized Phase 2 PrECOG Study (PrE0501)

Published:2013-08 Issue:8 Volume:8 Page:1075-1083
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Aisner Joseph,Manola Judith B.,Dakhil Shaker R.,Stella Philip J.,Sovak Mika A.,Schiller Joan H.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference29 articles.

1. Cancer Facts and Figures. 2013;American Cancer Society,2013

2. Paclitaxel and carboplatin in combination with gemcitabine: a phase I-II trial in patients with advanced non-small-cell lung cancer. Gruppo Studio Tumori Polmonari Veneto (GSTPV);Favaretto;Ann Oncol,2000

3. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer;Sandler;N Engl J Med,2006

4. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia;Arteaga;Semin Oncol,2002

5. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential Therapeutic Strategies for Lung and Breast Cancers through Understanding the Anti-Angiogenesis Resistance Mechanisms;International Journal of Molecular Sciences;2020-01-15

2. Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients;European Journal of Preventive Cardiology;2018-01-29

3. Maintenance Chemotherapy for Nonsmall Cell Lung Cancer;IASLC Thoracic Oncology;2018

4. Risk of rash associated with vandetanib treatment in non-small-cell lung cancer patients;Medicine;2017-10

5. Risk of gastrointestinal events with newly approved (after 2011) vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials;European Journal of Clinical Pharmacology;2017-07-15